Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide

Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients. Recent insight into the heterogeneous nature of GBM suggests a more personalized approach to treatment may be necessa...

Descripción completa

Detalles Bibliográficos
Autores principales: Weyhenmeyer, Birgit C., Noonan, Janis, Würstle, Maximilian L., Lincoln, Frank A., Johnston, Grainne, Rehm, Markus, Murphy, Brona M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308652/
https://www.ncbi.nlm.nih.gov/pubmed/27494880
http://dx.doi.org/10.18632/oncotarget.10973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308652/
https://www.ncbi.nlm.nih.gov/pubmed/27494880
http://dx.doi.org/10.18632/oncotarget.10973

Ejemplares similares